Sugi Predict

Sugi Predict / Compounds / SCHEMBL1309451

SCHEMBL1309451

SCHEMBL1309451

CC(C)(C)OC(=O)NCCCCCCCCCCN

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.71
▸ MAOA P21397 1/20 0.66
▸ MAOB P27338 1/20 0.66
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ CA1 P00915 8/20 0.56
▸ CA2 P00918 8/20 0.56
▸ CA12 O43570 6/20 0.56
▸ CA9 Q16790 6/20 0.56
▸ PAOX Q6QHF9 2/20 0.55
▸ EPHX1 P07099 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL989107 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL964035 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL1206249 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL146037 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL5866373 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL220281 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL1286925 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL368074 1.00 TDP1 (0.71) TDP1MAOAMAOBMEN1KMT2A
Hydrochloric Acid SCHEMBL2417149 0.98 TDP1 (0.69) TDP1MAOAMAOBMEN1KMT2A
Hydrochloric Acid SCHEMBL3231613 0.98 TDP1 (0.69) TDP1MAOAMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036705-A PROTAC compound of targeted PI3K alpha and preparation and application thereof 三亚深海化合物资源中心 2026-05-15 — — CN disclosed
EP-4731309-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS Paq Therapeutics Inc. (US) 2026-04-29 — — EP disclosed
US-20260109732-A1 LIPID AMINES MODERNATX INC (US) 2026-04-23 — — US disclosed
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2026-02-12 — — US disclosed
US-12521393-B2 Cytotoxicity targeting chimeras for CCR2-expressing cells GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-13 — — US disclosed
EP-4640280-A2 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-10-29 — — EP disclosed
EP-4384223-B1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-10-01 — — EP disclosed
US-20250281419-A1 LIPID AMINES ARES CAPITAL CORPORATION, AS AGENT 2025-09-11 — — US disclosed
US-12404285-B2 KRAS G12D proteolysis targeting chimeras PAQ Therapeutics Inc. (US) 2025-09-02 — — US disclosed
US-20250235531-A1 MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS MODERNATX, INC. (US) 2025-07-24 — — US disclosed
US-20110086858-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2011-04-14 — — US disclosed
US-20080318995-A1 N-Substituted Indenoisoquinolines and Syntheses Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-25 — — US disclosed
EP-1960366-A2 N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF Purdue Research Foundation (US) 2008-08-27 — — EP disclosed
WO-2007059008-A2 N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF PURDUE RESEARCH FOUNDATION (US) 2007-05-24 — — WO disclosed
EP-1580739-A1 An object comprising a functional layer DSM IP Assets B.V. (NL) 2005-09-28 — — EP disclosed
US-6646129-B2 Treatment of psoriasis and skin cancer LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-11-11 — — US disclosed
EP-0984936-B1 CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS LEO PHARMA AS WITH SECONDARY N (DK) 2003-09-03 — — EP disclosed
US-20020107400-A1 Cyanoguanidines as cell proliferation inhibitors LEO PHARMACEUTICAL PRODUCTS LTD. A/S 2002-08-08 — — US disclosed
US-6346520-B1 ANTITUMOR AND ANTICARCINOGENIC AGENTS; PSORIASIS LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) 2002-02-12 — — US disclosed
WO-2000061560-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2000-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318995-A1 N-Substituted Indenoisoquinolines and Syntheses Thereof GNAQ, NRAS, NPM1 TDP1 1868/4885MAOA 1700/4885MAOB 937/4885
US-20250235531-A1 MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS MUC1, RNMT, FABP2 TDP1 3192/4885MAOA 3814/4885MAOB 3505/4885
US-12404285-B2 KRAS G12D proteolysis targeting chimeras KRAS, NRAS, HRAS TDP1 3827/4885MAOA 4877/4885MAOB 4869/4885
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS CCR2, CCR1, CCRL2 TDP1 1585/4885MAOA 4638/4885MAOB 4342/4885
US-20250281419-A1 LIPID AMINES SGMS1, PHOSPHO1, SGMS2 TDP1 2561/4885MAOA 68/4885MAOB 71/4885
US-20110086858-A1 Compounds for the Treatment of Hepatitis C HAVCR2, SLC10A1, HCCS TDP1 3844/4885MAOA 1898/4885MAOB 891/4885
US-20020107400-A1 Cyanoguanidines as cell proliferation inhibitors CCNC, MKI67, CCNI TDP1 1512/4885MAOA 629/4885MAOB 302/4885
US-20260109732-A1 LIPID AMINES LDLR, NPC1, PHOSPHO1 TDP1 3880/4885MAOA 1793/4885MAOB 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.